SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus
Financing co-led by Janus Henderson Investors and Balyasny Asset Management, with participation from Adage Capital Management, HBM Healthcare Investments, OrbiMed and continued support from existing investors Proceeds to support advancement of Lycia’s LYTAC pipeline, including LCA-0061 for food
